The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Looking forward to ASH 2021: key updates in multiple myeloma
Samir N. Parekh, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, comments on key topics in multiple myeloma that will be discussed at the upcoming ASH annual meeting. There will be updates in immunotherapy, notably on the use of bispecific antibodies alone or in combination with other treatments, as well as on the long-term outcomes of upfront treatment with monoclonal antibodies. Single-cell approaches to understand the tumor microenvironment in multiple myeloma will be explored as well. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
